Alamar Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Alamar Biosciences

Tue 22:56

Alamar Biosciences Inc ALMR.OQ reported a quarterly adjusted loss of 19 cents​​ per share for the quarter ended September 30.  The mean expectation of five analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -26 cents to -15 cents per share.
Revenue was $33.55 million​; analysts expected $30.19 million. 
Alamar Biosciences Inc's reported EPS for the quarter was a loss of 19 cents​.
The company reported a quarterly loss of $13.34 million.
Alamar Biosciences Inc shares had fallen by 15.1% this quarter.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" 
Wall Street's median 12-month price target for Alamar Biosciences Inc is $33.00, about 12.3% above its last closing price of $28.94
This summary was machine generated from LSEG data November 3 at 10:56 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.21
-0.19
Beat
Jun. 30 2026 
-0.33
-0.22
Beat